JP2024511412A - コロナウイルスワクチン製剤 - Google Patents

コロナウイルスワクチン製剤 Download PDF

Info

Publication number
JP2024511412A
JP2024511412A JP2023558130A JP2023558130A JP2024511412A JP 2024511412 A JP2024511412 A JP 2024511412A JP 2023558130 A JP2023558130 A JP 2023558130A JP 2023558130 A JP2023558130 A JP 2023558130A JP 2024511412 A JP2024511412 A JP 2024511412A
Authority
JP
Japan
Prior art keywords
cov
months
seq
sars
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024511412A5 (https=
Inventor
スミス，ゲイル
ジェイ． マサレ，マイケル
ティアン，ジン－フイ
Original Assignee
ノババックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノババックス，インコーポレイテッド filed Critical ノババックス，インコーポレイテッド
Publication of JP2024511412A publication Critical patent/JP2024511412A/ja
Publication of JP2024511412A5 publication Critical patent/JP2024511412A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2023558130A 2021-03-22 2022-03-18 コロナウイルスワクチン製剤 Pending JP2024511412A (ja)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163164487P 2021-03-22 2021-03-22
US63/164,487 2021-03-22
US202163176825P 2021-04-19 2021-04-19
US63/176,825 2021-04-19
US202163177059P 2021-04-20 2021-04-20
US63/177,059 2021-04-20
US202163195986P 2021-06-02 2021-06-02
US63/195,986 2021-06-02
US202163280395P 2021-11-17 2021-11-17
US63/280,395 2021-11-17
US202163290439P 2021-12-16 2021-12-16
US63/290,439 2021-12-16
US202163292196P 2021-12-21 2021-12-21
US63/292,196 2021-12-21
US202163293468P 2021-12-23 2021-12-23
US63/293,468 2021-12-23
PCT/US2022/020974 WO2022203963A1 (en) 2021-03-22 2022-03-18 Coronavirus vaccine formulations

Publications (2)

Publication Number Publication Date
JP2024511412A true JP2024511412A (ja) 2024-03-13
JP2024511412A5 JP2024511412A5 (https=) 2025-03-27

Family

ID=83396030

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558130A Pending JP2024511412A (ja) 2021-03-22 2022-03-18 コロナウイルスワクチン製剤

Country Status (11)

Country Link
US (1) US20220332765A1 (https=)
EP (1) EP4313143A4 (https=)
JP (1) JP2024511412A (https=)
KR (1) KR20230160349A (https=)
AU (1) AU2022245141A1 (https=)
BR (1) BR112023019301A2 (https=)
CA (1) CA3213221A1 (https=)
IL (1) IL306088A (https=)
MX (1) MX2023011163A (https=)
TW (1) TW202304955A (https=)
WO (1) WO2022203963A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120227451A (zh) * 2018-03-19 2025-07-01 诺瓦瓦克斯股份有限公司 多价流感纳米颗粒疫苗
US10953089B1 (en) 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
WO2023196634A2 (en) 2022-04-08 2023-10-12 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024151583A2 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations Vii, Llc Vaccines and related methods
WO2024258829A1 (en) 2023-06-12 2024-12-19 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025054236A2 (en) 2023-09-06 2025-03-13 Flagship Pioneering Innovations Vii, Llc Sars-cov-2 vaccine compositions and related methods
WO2025088585A1 (en) * 2023-10-25 2025-05-01 Novavax AB Saponin-based adjuvants and methods of characterizing same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2968510B1 (en) * 2013-03-14 2019-10-09 President and Fellows of Harvard College Nanoparticle-based compositions
US10953089B1 (en) * 2020-01-27 2021-03-23 Novavax, Inc. Coronavirus vaccine formulations
US20210228707A1 (en) * 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines
JP2023512519A (ja) * 2020-01-31 2023-03-27 ベス イスラエル ディーコネス メディカル センター インコーポレイテッド コロナウイルス感染症を予防および処置するための組成物および方法－ｓａｒｓ－ｃｏｖ－２ワクチン
US10906944B2 (en) * 2020-06-29 2021-02-02 The Scripps Research Institute Stabilized coronavirus spike (S) protein immunogens and related vaccines

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"PRELIMINARY EFFICACY OF THE NVX-COV2373 COVID-19 VACCINE AGAINST THE B.1.351 VARIANT", MEDRXIV, JPN5025000270, 3 March 2021 (2021-03-03), pages 1 - 30, ISSN: 0005831070 *
FRONTIERS IN MICROBIOLOGY, vol. 11, no. 298, JPN5025000273, 2020, pages 1 - 19, ISSN: 0005831073 *
MBIO, vol. Vol.12, No.2, e02648-20, JPN5025000271, 2 March 2021 (2021-03-02), pages 1 - 10, ISSN: 0005831072 *
NATURE COMMUNICATIONS, vol. 12, no. 372, JPN5025000269, January 2021 (2021-01-01), pages 1 - 14, ISSN: 0005831069 *
SCIENCE, vol. 369, JPN5025000272, 2020, pages 806 - 811, ISSN: 0005831071 *

Also Published As

Publication number Publication date
AU2022245141A9 (en) 2024-02-22
EP4313143A4 (en) 2025-06-18
BR112023019301A2 (pt) 2023-12-05
AU2022245141A1 (en) 2023-10-05
CA3213221A1 (en) 2022-09-29
KR20230160349A (ko) 2023-11-23
US20220332765A1 (en) 2022-10-20
MX2023011163A (es) 2024-02-27
IL306088A (en) 2023-11-01
EP4313143A1 (en) 2024-02-07
TW202304955A (zh) 2023-02-01
WO2022203963A1 (en) 2022-09-29

Similar Documents

Publication Publication Date Title
US12472246B2 (en) Coronavirus vaccine formulations
JP7792339B2 (ja) コロナウイルスワクチン製剤
JP2024511412A (ja) コロナウイルスワクチン製剤
US20250025549A1 (en) Coronavirus vaccine formulations
JP7317796B2 (ja) 呼吸器疾患を治療するための方法および組成物
JP2023538667A (ja) Ｓａｒｓ－ｃｏｖ－２感染症に対するワクチン
JP2023538665A (ja) トコフェロール含有スクアレンエマルションアジュバントを有するｃｏｖｉｄ－１９ワクチン
RU2845642C1 (ru) Вакцинные составы против коронавируса
CN117769433A (zh) 冠状病毒疫苗制剂
CN118613279A (zh) 冠状病毒疫苗制剂
HK40088999A (zh) 冠状病毒疫苗配制品
HK40110532A (zh) 冠状病毒和流感病毒组合物和其使用方法
CN121511094A (zh) Sars-cov-2疫苗组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260401